Hitachi, AccSys deliver first PET isotope production system utilizing a linear accelerator

TriMed Staff | | Health Imaging | Screening
Hitachi Ltd. and subsidiary AccSys Technology Inc. have delivered what they say is the first dedicated radioisotope production system in Japan utilizing the Positron Tracer Production system. The linear accelerator was developed by AccSys for use in positron emission tomography (PET).

Hitachi General Hospital of Hitachi Ltd. will begin PET scans using isotopes produced with the system in the second quarter. Hitachi and AccSys intend to bring this radioisotope production system to market beginning next year.

AccSys manufactures compact ion linear accelerator for medical, industrial and research operations and introduced the Positron Tracer Production system line of positron tracer production systems in 1998.

The system is designed to produce clinical quantities of the positron tracer 18F-FDG for PET imaging. Through the adoption of highly advanced cancer examination technologies, such as PET, Hitachi General Hospital looks to play a primary role as a cancer treatment facility in Japan.

TriMed Staff

Related Content

FDA clears AI tool that flags signs of heart disease in chest CT scans
Patients without PCPs struggle to access lung cancer screening, despite eligibility
Breast cancer rates among women in their 30s are on the rise
Singing radiologist pens song to clear up confusion about breast cancer screening recs
AI loaded onto mammography systems can flag possible cancers in real time to speed workflows
Over half of eligible women skip their mammogram

Around the web

Cardiovascular Business
Global shortage of nuclear imaging isotopes may be over

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

Cardiovascular Business
‘A huge win’: CMS significantly increases Medicare payments for cardiac CT

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.

Cardiovascular Business
FDA clears AI tool that flags signs of heart disease in chest CT scans

The newly cleared offering, AutoChamber, was designed with opportunistic screening in mind. It can evaluate many different kinds of CT images, including those originally gathered to screen patients for lung cancer. 

Design by Adaptive Theme
Trimed Popup
Trimed Popup